TITLE:
Interrupted Etanercept Therapy: A New Case Report
AUTHORS:
Waqas S. Abdulwahhab, Alaa S. Mehair
KEYWORDS:
Adherence, Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α), Etanercept, Interrupted Therapy, Psoriasis
JOURNAL NAME:
Journal of Cosmetics, Dermatological Sciences and Applications,
Vol.11 No.2,
April
15,
2021
ABSTRACT: Psoriasis is a chronic, immune-mediated,
inflammatory disease with a high prevalence in the general population (2%). The
anti-tumor necrosis factor receptor etanercept is Food and Drug Administration
(FDA) approved for the treatment of moderate-to-severe plaque psoriasis. Both
continuous and interrupted etanercept therapy is effective and well-tolerated.
This report aims to document a new case presentation of psoriasis on
intermittent etanercept injection throughout 36 weeks with long-lasting
sustained efficacy and no risk factor. Case Report: A 39-year-old adult male
patient with long-standing chronic plaque psoriasis for 15 years duration
without joint involvement started loading dose treatment of etanercept
injection in whom due to his work circumstances not taken maintenance therapy
and showed-up at the clinic after 36 weeks from first induction therapy when
partial relapse of psoriatic lesions appear in last week with continued
improvement when reintroducing loading treatment on followed-up over the next
36 weeks. Conclusion: Intermittent etanercept therapy considers effective for
36 weeks with prolonging sustained efficacy and without adverse effect.